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Background: A clinical feasibility study was undertaken at a single center of long-term intra-cerebroventricu-
lar drug delivery of the anti-seizure medication valproic acid, into the cerebrospinal fluid (CSF) in order to
treat drug resistant focal seizures, using an implantable infusion system. The primary objective was to estab-
lish the dose range of VPA administered in this manner. Secondarily, safety, pharmacokinetics (PK) and a pre-
liminary estimate of effectiveness were evaluated.
Methods: In this single arm study, five adult subjects, with 29234 focal onset seizures per month from a sei-
zure focus involving the mesial temporal lobe were implanted with the system (clinicaltrials.gov identifier
NCT02899611). Oral valproic acid (VPA) had previously been ineffective in all subjects. Post-surgery, pharma-
cokinetic studies of CSF infused VPA were performed. Valproic acid doses were increased stepwise in a stand-
ardised protocol.
Findings: The procedure and implantation were well-tolerated by all subjects. Four subjects responded with
> 50% seizure reduction at the highest tested dose of 160 mg/day. Two subjects experienced extended peri-
ods of complete seizure freedom. All five subjects reported significant quality of life improvement. No clinical
dose limiting side effects were encountered and there was no evidence of local periventricular toxicity in
three subjects who were evaluated with imaging (T2 MRI). Side effects included nausea and appetite loss but
were not dose-limiting. Mean CSF valproic acid levels were 45 mg per ml (range 20120 mg per ml), with
corresponding serum levels of 414 mg per ml. Subjects have received therapy for up to 2.5 years in total .
The efficacy analysis presented focuses on the period of time with the current pump with a mean 12.5
months, range 11.515 months. Pump failure requiring reimplantation was a significant initial issue in all
subjects but resolved with use of pumps suitably compatible with long-term exposure to valproic acid.
Interpretation: The study demonstrated that chronic intraventricular administration of valproic acid is safe
and effective in subjects with medically refractory epilepsy over many months. The procedure for implanting
the infusion system is safe and well-tolerated. High CSF levels are achieved with corresponding low serum
levels and this therapy is shown to be effective despite unsuccessful earlier use of oral valproate prepara-
tions. Drug side effects were minimal.
Funding: The study was funded by Cerebral Therapeutics Inc., Suite 137 12635 East Montview Blvd Aurora CO
80045.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)rtment of Medicine, The University of Melbourne, 35 Victoria Parade, Fitzroy, 3065 VIC, Australia.
).
Ltd. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Research in context
Evidence before this study
We searched PubMed, Google Scholar, and IEEExplore with the
terms “intra-cerebroventricular” or “ventricular” or “intraven-
tricular” with “infusion” or “injection” or “drug” or “therapy” or
“treatment” or “delivery” and “epilepsy” for human and animal
studies published between Jan 1, 1965, and February 2019. We
did not restrict publications by language. Whilst there was
some evidence for efficacy of anti-seizure drugs administered
using this approach in animal models, we could identify no
human studies examining this. There were numerous studies
utilizing this means of administration for a variety of other
medication however, chiefly anti-neoplastic agents.
Added value of this study
This study is the first in humans that provides continuous
administration of an anti-seizure medication via this route. The
pharmacokinetics of intraventricular valproate were estab-
lished, and the degree to which the drug crosses into the
peripheral circulation. The tolerability of relatively high cere-
brospinal fluid levels of valproate achieved was clarified.
Implications of all the available evidence
This proof-of-concept study shows that intraventricular anti-
seizure administration is possible and effective in humans. The
study provides an important first step towards the develop-
ment of new therapeutic strategies as well as new insights into
the mechanisms of action and side effects of anti-seizure drugs.
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Epilepsy is a common and serious neurological problem affecting
over 60 million people worldwide [1]. At least 30% of affected individ-
uals are resistant to current drug therapies, a proportion that has not
diminished despite the increasing number of available agents [2-4].
Additionally, patients often experience significant side effects, both
acute and chronic, in part through the systemic effects of anti-seizure
drug (ASD) use [5]. Drug resistant epilepsy is a major therapeutic
challenge, leading to the development of several novel approaches in
recent years including thalamic stimulation [6,7], responsive neuro-
stimulation [8], and laser interstitial thermal therapy [9], chiefly as
alternatives to resective surgery.
Improving delivery of anti-seizure medications is another area of
exploration. Application of anti-seizure drugs to a restricted brain
region can produce high concentrations of the drug in the region of
seizure onset and spread, which may provide control of seizures
while potentially avoiding the peripheral and central side effects that
limit oral drug administration. Focal drug delivery is a theoretically
appealing treatment alternative for patients with medically refrac-
tory epilepsy. Treatment options such as the intracranial implanta-
tion of polymer-based drug delivery systems have been explored
extensively in animal models [10]. These implants slowly break
down following implantation, releasing drug locally to the implant
site, or by spreading through the CSF if implanted into CSF spaces.
Recent studies have demonstrated some success at using similar bio-
degradable implants to treat animal models of several other neuro-
logical disorders with focal pathologies such as Parkinson’s disease,
Huntington’s disease and Alzheimer’s disease [11]. Studies in animal
models of epilepsy to date have been less successful however, chiefly
as it is difficult to provide an implant with a sufficiently long lifespan.
A range of alternative methods of ASD delivery directly to the seizure
focus has been described [12].Delivery of medications directly to the brain via an intra-cerebro-
ventricular route (ICV Infusion) has been used in a variety of short-
term clinical scenarios, particularly leptomeningeal cancer and
meningitis. This method has been shown to be safe, with complica-
tions relating to the device and its implantation, specifically in regard
to infective complications [13].
Valproic acid is a broad-spectrum anti-seizure medication known
to be effective for tonicclonic, myoclonic, tonic and absence seiz-
ures, as well as focal seizures [14,15]. VPA was chosen for this study
as a suitable formulation could be prepared and because prior animal
studies suggested possible efficacy [16,17].
Generally, valproic acid is well tolerated although significant side
effects including nausea, weight gain, tremor, hair change and seda-
tion limit its systemic usage. Hepatotoxicity is rare. Teratogenicity in
particular has emerged as a significant problem limiting use in
women of child-bearing potential, and this risk seems to be dose-
related [18]. Intra-cerebroventricular administration of VPA could
potentially avoid VPA systemic toxicity, producing a high concentra-
tion of the drug in the brain, but with low serum levels, and conse-
quently less peripheral toxicity. This direct to CSF mode of
administration has the potential to increase central nervous system
toxicity however, as many of these adverse effects are presumed to
be the result of cerebral toxicity which could vary depending upon
the distribution of valproic acid in the brain with ICV administration.
Little is known of human CSF levels of VPA. The therapeutic range
for valproic acid (total) in serum is 50125mg/mL, and the toxic level
is greater than 150 mg/mL. The therapeutic range for unbound val-
proic acid is 622 mg/mL in humans. Primate average CSF levels after
loading with oral doses targeting 2£ human blood levels ranged
from 18 to 20 mg/mL [19]. Human average CSF Levels steady state
concentrations have been recorded in the range of 3  5 mg/mL,
though from very limited data [20-22].
We describe dose-escalation of a continuous infusion of valproic
acid after implantation of a pump infusion system directly into one
lateral cerebral ventricle in proximity to the presumed seizure focus
in subjects with mesial temporal onset of seizure activity. We
describe the results and side effects experienced to date.
The primary objective of this study was to establish the dose range
of ICV administration of valproic acid. Secondarily, safety, pharmacoki-
netics and a preliminary estimate of effectiveness were evaluated.
The anatomical target for valproic acid drug delivery in this clini-
cal study was the hippocampus, which is immediately adjacent to the
temporal horn of the lateral ventricle. Based on the rate of diffusion
within fluid spaces and from fluid spaces into the brain, the anatomic
continuity of the lateral ventricle and what is known about the rate
of CSF emptying from the ventricle [23], placing the catheter tip in
the frontal horn was thought to potentially accomplish high doses of
medication in the periventricular areas of the lateral ventricle includ-
ing the temporal horn because of the lack of barriers between the dif-
ferent segments within the lateral ventricle, relatively slow
movement of CSF in the ventricular system and the rapid movement
and mixing in the ventricle caused by cerebral vascular pulsations.
Methods
Study design and subjects
This was a dose-ranging study to establish the dose range of ICV
valproic acid delivery, with a brief period of blinding during dose
escalation for the initial four weeks, designed mainly to obtain an
unbiased report of side effects.
We recruited adult subjects (1865 years of age) with medically
refractory focal seizures with or without secondary generalization
who averaged four or more disabling focal seizures per month for the
30 days over the three most recent consecutive 30-day periods, with
no 30-day period with less than two seizures. Current use of
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Research Ethics Committee, St. Vincent’s Hospital, Melbourne
(approval number HREC 014/16). All subjects were recruited from a
single center. The study was registered on clinicaltrials.gov, identifier
NCT02899611.
Valproic acid was administered continuously via ICV delivery for
50 days during a blinded evaluation period in order to establish maxi-
mum tolerated dose (MTD), after which the dose was escalated fur-
ther according to a predefined schedule.
The primary objective was to establish the dose range of VPA
administered in this manner. The dose range was to be limited by the
MTD, which is the highest dose tolerated without experiencing a
dose-limiting adverse event, or alternatively the highest dose in a
provided dose escalation table. Secondarily, safety, pharmacokinetics
(PK) and a preliminary estimate of effectiveness were evaluated.
After providing informed consent, subjects were screened for
entrance criteria and all subjects continued their routinely prescribed
orally administered ASDs throughout the study duration, except
when adjustment was required on clinical grounds. Clinical assess-
ments, adverse events (AEs), seizure diary, concomitant medications,
blood samples and CSF were collected and reviewed at designated
time points. MRI Scan, EEG, ambulatory video-EEG and ECG studies
were also performed. Subjects had their surgery, dose changes and
PK performed in an inpatient or infusion clinic setting. 6 subjects
were assessed and considered eligible. 1 subject declined further par-
ticipation as it proved too difficult for them to access the hospital
facility regularly from an interstate location.
In order to identify a starting dose, we extrapolated from the liter-
ature dosing ratios of systemic versus intrathecal (IT) or intra-cere-
broventricular (ICV) drug administration for conditions other than
epilepsy. There was considerable variation between the dose
administered systemically and intrathecally or ICV, with intrathe-
cal concentration ranges between 1/500th and 1/10th of systemic
dose [24]. Further, based on data in Appendix V and VI, as well
as previous experience with ICV morphine and baclofen chemo-
therapy, we created a schedule for increasing ICV doses from 1/
400th of the oral dose in the standard range of valproate, moni-
tored by careful observation for potential side effects, gradually
to a dose of up to 1/10th of the oral dose of valproate. The start-
ing dose was based on pre-clinical data, clinically established CSF
valproic acid levels from oral and IV administration as well as
extrapolating from the experience with intrathecal morphine and
baclofen delivery [25].
The ICV valproate dose was initially escalated stepwise through
Day 50, if tolerated or stopped earlier upon establishment of a sub-
ject’s maximum tolerated dose (MTD). Dose escalation is described in
detail in Table 1. After the initial escalation, subjects were then fur-
ther escalated stepwise from 60 mg/day up to 160 mg/day. The devi-
ces were refilled at varying intervals according to the dose escalationTable 1
Drug titration schedule.
Study week Dosing Study day
(§3 days)
Estimated Fra
for a 60 kg pe
1 Level 0 Days 17 Vehicle (pres
normal sal
2 Level 1 Day 8 5% of CPTD
3 Level 2 Day 15 10% of CPTD
4 Level 3 Day 22 25% of CPTD
5 Level 4 Day 29 50% of CPTD
6 Level 5 Day 36 60% of CPTD
7 Level 6 Day 42 75% of CPTD
8 Level 7 Day 49 100% of CPTD
X Placebo week randomly
inserted
Day 56 + (8 weeks plus) Placebo (pres
normal sal
Last Day Day 64 or 9 weeksand response, but all were maintained on approximately monthly
cycles of refills when optimal doses were reached.
Both the subjects and the assessing physician remained blinded to
the treatment dose during the Blinded Evaluation Period. Subjects
were able to continue in an open-label evaluation period for 52
weeks following the Blinded Evaluation Period. Subjects who com-
pleted the Open-Label Evaluation Period and responded well to treat-
ment were able to continue in the Open-Label Extension Period for
up to two years (approximately 104 weeks).
The primary safety outcomes were measured via the serious
adverse event (SAE) rate. Safety was also assessed via adverse events,
vital signs, physical exams, changes in concomitant medications, use of
rescue medications, neuropsychological testing, and laboratory tests.
The primary efficacy outcome was measurement of change in the
number of seizures. Efficacy was also assessed via seizure type and
severity from seizure diary data, measured EEG readings, use of rescue
medication, neuropsychological testing, and decrease in oral ASD use.
Statistical analysis
Given the small number of subjects it was not considered appro-
priate or practical to perform statistical analysis.
Drugs
Epilim (Sanofi-Aventis) was compounded with 0.4% citrate
(Medical Components, Inc., PA) to achieve the desired sodium val-
proate concentrations (pH 7.6) and used to fill the implanted reser-
voir of the intrabdominal drug infusion pump for CSF delivery (see
below).
Procedures
Screening verified seizure frequency and anatomic localization of
seizure onset, blood tests for a complete blood count, liver and kidney
function, assay for HIV infection urinalysis, pregnancy test for females
were performed and a recent MRI was performed if not done in the
prior three years. Neuropsychological studies were performed. There
was a baseline ECG and EEG as well as a one-week continuous EEG
with an ambulatory video-EEG system. Subjects kept a daily validated
electronic seizure diary (EpiDiary, Irody).
The system was comprised of an abdominal CSF infusion pump
(Flowonix, Medtronic, or Tricumed) with an intraventricular cathe-
ter, and an Ommaya reservoir connected to an intraventricular cath-
eter. Frameless stereotaxy was used (Axium Medtronic) to plan a
right frontal curve incision. Two burr-holes were made at Kocker’s
point in the sagittal plane to access the frontal horn of the right lat-
eral ventricle. The Ommaya reservoir and catheter were placed first
in the anterior burr-hole (Fig. 1). Using a Stimloc Burr-hole coverction of CPTD
rson
ICV valproate
IDaily Dose Concentration (mg/ml)
ervative-free
ine)
Vehicle (programmed as
0.6 mg/day)
Vehicle (programmed as
1 mg/mL)
3.0 mg/day 5 mg/mL
6 mg/day or MTD 10 mg/mL
15 mg/day or MTD 25 mg/mL
30 mg/day or MTD 50 mg/mL
36 mg/day or MTD 60 mg/mL
45 mg/day or MTD 75 mg/mL
60 mg/day or MTD 100 mg/mL
ervative-free
ine)
Placebo (programmed as
0.6 mg/day)
Placebo (programmed as
1 mg/mL)
Fig. 1. Location of Intraventricular Catheter and Ommaya reservoir.
4 M. Cook et al. / EClinicalMedicine 22 (2020) 100326(Medtronic) the drug delivery catheter was placed and secured in
the burr-hole posterior to the Ommaya device to avoid inadvertent
puncture when sampling CSF. An incision and pocket were made
above the abdominal fascia in the right lower abdomen to contain
the pump (Fig. 2).
For the first post-operative week, the pump infused normal saline.
The blinded study period ran from Day 8 to 50 with weekly visits,
during which blood and CSF samples were taken. Follow-up neuro-
logical exams, quality of life questionnaires, collection of seizure dia-
ries, reports of any side effects, and EEGs were performed during the
study. At 52 weeks, the subject entered an open-label phase.Fig. 2. Location of intra-abdominal pump and subcutaneous catheter.The catheter was passed subcutaneously from the frontal area to
the abdomen with a relieving incision over the right mastoid. All
implantations were right-sided. Post-operatively a contrast CT study
was performed to confirm correct location of the catheter systems
and patency (Fig. 3).
The drug titration schedule is shown in Table 1. A placebo week
was inserted at a random week during the protocol, primarily to vali-
date side effect reporting.
Role of funding body
The sponsor had roles in study design; data collection, analysis,
and interpretation; and writing of the article. DA is the CEO and
founder; ED is the VP of Clinical Development and SP is a Research
Manager of the sponsoring body. RF holds stock options in the spon-
soring company. No other authors received compensation. All
authors had full access to all study data. The corresponding author
made the decision to submit the paper for publication and produced
the final draft.
Subjects
Five adult (four females, one male) subjects (age 2538 years),
with severe long-standing focal epilepsy were refractory to more
than six ASDs for many years (including valproate greater than 1000
mgs per day). Valproate had been discontinued in all primarily
because of lack of efficacy. When previously taking oral valproate, all
noted minor sedation, 4 subjects had also complained of tremor, and
2 subjects significant weight gain. Subjects, who were implanted
experienced 29234 complex focal seizures monthly in the month
prior to trial commencement, were evaluated by subject-reported
seizures using an electronic diary, had undergone extensive clinical
and radiological assessment including video-EEG, MRI and EEG-MEG
(clinical and demographic features are shown in Table 2), and had
electro-clinical and/or imaging features consistent with seizures
involving (although, not necessarily originating in) the mesial tempo-
ral region. CSF samples were taken via the Ommaya reservoir and
used to establish CSF drug levels and kinetics. Peripheral blood sam-
ples were taken for systemic ASD levels. Doses were increased step-
wise to a predetermined level according to a protocol against
suitable clinical parameters. Seizure records were kept using an elec-
tronic diary system.
Results
Safety
The procedure, implantation and intra-cerebroventricular VPA
were well-tolerated by all subjects.
No clinical dose-limiting side effects were encountered, and no
evidence of local toxicity was detected in three subjects evaluated
with MRI T2 imaging. Subjects often noted a persistent central ‘cold’
feeling, often as the dose reached an effective level. Mild nausea and
appetite loss were often reported. Insomnia was a frequent but tran-
sient phenomenon at dose increases. A single female patient devel-
oped minor hair loss at the upper limit of the VPA dose. Other
familiar side-effects of VPA, such as tremor, sedation, and appetite
increase were not observed in any subjects. No changes were
detected otherwise on physical examination, subjects remained alert
and comfortable and wished to continue the therapy despite these
side-effects.
We performed T2 weighted non-contrast MRI scans to screen for
signs of periventricular T2 weighted changes which could suggest
local effect of ICV infusion. We were able to demonstrate in these
three subjects that there was no peri ventricular T2 changes or the
signs of edema associated with ICV therapy exposure. The range of
Fig. 3. X-Rays of abdominal pump and catheter location. Shown in A is the location of the abdominal pump (arrow), with a surgical device previously implanted for obesity therapy
indicated (asterisk). In B the location of the intraventricular delivery catheter (single arrowhead) and Ommaya reservoir (double arrowhead) are shown.
M. Cook et al. / EClinicalMedicine 22 (2020) 100326 5exposure was 48 months for dose ranges of 40100 mg/day during
which the MRI scans were conducted.
Subjects have had ICV therapy for up to 2.5 years at the time of
submission, and all patients continue to receive ICV VPA treatment.
Pump failure was the major complication and occurred with the first
pump chosen for the study in all subjects after approximately five
months of use, necessitating removal and reimplantation of a new
device. The clinical benefits of the study were by this time sufficiently
clear to justify re-implantation. Pump failure was quickly identified
clinically as seizures promptly returned to pre-trial levels and con-
firmed with estimation of residual pump volumes. The second pump
chosen for the study also failed after approximately five months and
again required removal and reimplantation. The reasons for failure
were not clear despite engineering review of the devices, thoughTable 2
Patient characteristics.
Age
@ dx/ yrs
Localization/Imaging Etiology Semiology
28/f 12 Band heterotopia. Bilateral. PET
left temporal hypometabolism
Deja vu, nausea, occasionally
visual field disturbance.
Loss of contact. Posturing
right arm, frequent GTCS
41/f 24 Periventricular nodular
heterotopia
Olfactory aura, loss of con-
tact, left sided weakness
40/f 20 Encephalitis, clear bilat MTS on
MRI, Bilateral mesial
temporal hypometabolism on
PET
Deja vu, olfactory or gusta-
tory aura, loss of contact.
Occasional GTCS
37/m 30 Post traumatic? Olfactory aura, Deja vu oral
and manual automatisms,
vocalization, loss of
awareness, frequent GTCS
PET normal
MRI normal
53/f 48 Non-lesional on MRI and PET.
MEG left mesial temporal
Epigastric aura, confusion,
loss of contact
Abbreviations: CBZ  carbamazepine, CLZ  clonazepam, LCM  lacosamide, LEV  levetira
RTG  retigabine, TPM  topiramate, VPA  valproic acid, ZNS  zonisamide, LOA - loss of awith later pumps it was noted the silicone components of the system
had been affected, likely due to the drug formulation.
One patient experienced skin erosion over the Ommaya reservoir
leading to removal of the Ommaya reservoir, catheter, and drug deliv-
ery catheter. It was later successfully re-implanted, although without
the Ommaya reservoir. In another patient, an intra-abdominal pump
device became infected after six months. It was removed and re-
implanted. Other complications included pain and neck discomfort
related to the catheter. An Ommaya reservoir was removed from
another patient after returning persistently positive CSF cultures (Pro-
pionibacterium acnes), with a pleocytosis (6 polymorphonuclear cells)
though the patient was well. After normal lumbar CSF studies, it was
elected to remove the Ommaya and catheter alone from this patient
and clinically monitor, but to continue delivery of ICV valproatePresumed Epileptogenic
zone
Sz freq Failed Medications
MEG and ictal scalp EEG
strongly localizing to left
mesial temporal lobe
Several/week VPA, LEV, PMP, ZNS, LCM,
PHB, CLZ
Mesial temporal clinically
and on EEG/MEG
Several/week VPA, LEV, CBZ, CLB, ZNS,
PMP, OCZ
Bilateral MTS with bilateral
onset on scalp VEEG.
Interictal independent
bitemporal spikes
Several/week VPA, TPM, PMP, CBZ, LMG,
CLZ, PHT
Felt mesial temporal on clin-
ical grounds
Several/month PHT, VPA (cognitive issues),
LMG, LEV, CBZ, ZNS, PMP,
TPM, LCM, PHB
L Mesial temporal on MEG
and bilateral HC depth
Several/week LEV, VPA, TPM, CBZ, LCM,
PMP
cetam, LTG  lamotrigine, OXC  oxcarbazepine, PHT  phenytoin, PRP  perampanel,
wareness, GTCS  generalized tonic-clonic seizure.
Table 3
Monthly seizure reduction results for all subjects.
Subject Monthly% Change based on
Average (n) as of 15 Jan 2019
Monthly% Change Through
March based on Average (n)
Monthly% Change Through
March based on Median
Last 3-month% Change
based on Average (Jan15-
Apr15)
Last 3-month% Change
based on Median (Jan15-
Apr15)
0101 69% (6) 75% (9.5) 75% 100% 100%
0102 97% (4) 94% (7.5) 100% 65% 65%
0103 32% (7) 57% (10) 42% 92% 91%
0104 55% (5) 27% (8) 31% 59% 55%
0107 61% (2) 64% (6.5) 64% 71% 78%
Average 63% 63% 62% 77% 78%
6 M. Cook et al. / EClinicalMedicine 22 (2020) 100326because of the marked clinical improvement. The patient remains well
and there are no signs of systemic or CNS infection.
In terms of device adverse events, a total of nine were serious and
required intervention to resolve. The majority (7 of 9) were primarily
related to pump failure and the rest (2 of 9) were related to infection
primarily related to repeated transcutaneous access for pharmacoki-
netic drug levels. A new pumpwas chosen free of silicone components.
These specialized systems have been functioning for more than 15
months (mean 12.5 months, range 11.515 months) with a total of
62-months of on-therapy across all subjects. In addition, drug sam-
pling from the Ommaya was done in a more limited and modified
way. The combination of these modifications has resulted in no subse-
quent device-related adverse events with the current pump system
being used by the subjects.Effectiveness
There are currently five subjects implanted with the new pump
and receiving therapy. Across these five subjects there is a total of 62
months of active therapy (mean 12.5 months, range 11.515
months). We performed an analysis of seizure frequency compared
to baseline for these subjects.
As of data-cutoff at 30 June 2019, mean monthly seizure reduction
was 70% (range 4594%, n = 5). Responder rate of at least a 50% sei-
zure frequency reduction was 80% with maximum doses of
80160 mg/day (Table 3 & Fig. 4). When looking at the most recent
three months, representative of all subjects at their highest doses
mean seizure reduction was 80% (range 46100%, n = 5). Seizure free-
dom has been achieved in 60% of the subjects with one subject now
seven months seizure free and two other subjects having achieved
seizure freedom periods of greater than four weeks. Improvement
was dose-dependent, such that some subjects demonstrated reduc-
tion or elimination of seizures as dosing approached 160 mg per day.Patient reported outcomes
As part of our approach to patient outcomes beyond seizure
reduction, we also measured the Quality of Life in Epilepsy 10 ques-
tions (QOLIE 10) and the Beck Depression Index (BDI). Due to patient
flow and early pump failures, this was not done on all subjects. Base-
line and follow-up QOLIE-10 and BDI scores were obtained on three
of the five subjects. Across those three subjects we found improve-
ments in two of three with QOLIE 10 and all three subjects with BDI.
Of the three subjects QOLIE 10 data was collected from, we saw an
average improvement of 26% in scores (37%, 33%, 7% respectively
with mean point reduction of 8; range 416). Most notably were
marked improvements in energy (average three-point improve-
ment), social limitations (average three-point improvement) and fear
of seizures (average two-point improvement). We also saw clinically
meaningful BDI improvements. All three tested subjects dropped at
least one depression classification and average of 55% score reduction
(12 points).Valproate pharmacokinetics
During the dose-escalation phase of the study from 2.5 mg to 60
mgs per day, valproate CSF and serum levels were sampled from zero
to 90 min via the Ommaya reservoir, and for serum at intervals up to
24 h. During the open-label phase when the drug was further esca-
lated, zero time point CSF samples were obtained. This data allowed
us to understand relative CSF levels and serum levels for given ICV
doses, as well as CSF half-life of valproic acid when administered ICV
(Figs. 5 & 6).
In the initial dose escalation phase, CSF valproate levels averaged
45 micrograms/ml (range 2070), with corresponding serum levels
of 4 micrograms/ml. At the later dose escalation phase, the CSF levels
increased to 160 and serum levels to 17 micrograms per ml. Pharma-
cokinetic modeling demonstrated that the CSF half-life was 20 min.
The maximum CSF valproate level achieved was 280 for a prescribed
daily dose of 160 mg/day. High Peak CSF levels were observed
220 times that predicted based on serum free and highest levels
seen with animal and human studies. Low serum levels were seen,
with free levels 10% of CSF levels, likely accounting for fewer
observed systemic side effects. At 45 mg/day doses of valproate,
the CSF/Bound plasma valproate ratio was 10:1 and the CSF/
plasma free valproate was closer to 100:1, an inversion of the
usual CSF/Serum ratio.Discussion
This pilot study is the first demonstration of chronic ICV therapy
as a potentially effective strategy in medically refractory epilepsy.
Chronic intraventricular administration of valproic acid appears to
safe and effective, and the procedure is well tolerated. Problems
related to the pump reliability and infections were the major compli-
cations. High CSF levels are achieved with low serum levels and are
shown to be effective despite unsuccessful earlier use of oral val-
proate and other ASD preparations.
The therapy was clearly efficacious, despite the very refractory
nature of the epilepsy in these subjects. Pump failure provided a
striking example of this, with prompt resumption of seizures to pre-
study severity, with control rapidly being re-established on recom-
mencement of ICV infusion.
We experienced a significant number of complications, primarily
related to mechanical failure of the pump systems. Potential causes
included unanticipated interactions between the valproate and
pump components (despite initial compatibility testing for one
month) and resolving these has led to re-engineered pumps that
have satisfactory performance and lifespan. Other relevant factors
may include changes of the viscosity of the valproate at higher con-
centrations and pump temperature. The infection rate is comparable
to other published data for Ommaya reservoirs, with rates of 1525%
previously described [26,27]. Similarly, the rate of pump complica-
tions is similar to that seen in studies examining complication rates
for devices implanted for spinal cord complaints [28-30].
Fig. 4. Dose response curves for individual patients. Monthly percentage changes are shown.
Fig. 5. CSF Valproate PK Levels versus Dose for Subject 0101.
M. Cook et al. / EClinicalMedicine 22 (2020) 100326 7Very high peak CSF levels of valproic acid were observed, but sig-
nificant valproate toxicity was not encountered. It was particularly
surprising that tremor and sedation were not observed indicating
that the mechanism of these side effects may not be through direct
valproate CNS toxicity as previously assumed. Alternatively, the CNS
toxicity may be mediated in brain regions that are not exposed to the
very high levels encountered in the periventricular regions, such as
the brainstem or cerebellum. Kinetics of brain tissue penetration,
uptake into the brain substance and half-life might limit exposure of
other cerebral structures to valproate, but this hypothesis will require
future testing. Tremor is reported to occur in up to 50% of patients
taking valproate in other studies [31], and appears to be dose-related.
Interestingly, mild reversible alopecia developed in a single patient at
the maximum dose of valproate after two years of use after a dose
escalation. This side effect is recognized in 11% of those administered
valproate [32] and is regarded as unrelated to dose and occurring
within the initial six months of use. Weight gain, a common and often
limiting side effect of valproate in clinical practice, was conspicuously
absent despite having been a problem for these same subjects when
given as an oral preparation prior to this study. This is often also
Fig. 6. CSF and Serum Valproate Pharmacokinetics. Valproate dose 45 mg/day, CSF lev-
els free valproate, serum levels protein bound valproate.
8 M. Cook et al. / EClinicalMedicine 22 (2020) 100326presumed to have a central basis, though the pathogeneticmechanism
underlyingthis isuncertain.Verotti [33]notesthatmedication-induced
weightgain ismost likely complexandmultifactorialwithregulationat
peripheralandcentrallevelsbyvariousappetite-regulatingneuropepti-
desandcytokines thatactwithinthehypothalamustoaffect foodintake
andenergyexpenditure.Otherexplanationshaveincludeddysregulation
of thehypothalamic system, effect onadipokine levels, hyperinsulinae-
mia,insulinresistanceandgeneticsusceptibility.
We observed steady and sustained peak CSF levels of valproate
and widening of the therapeutic window through the combination of
high steady state CSF levels, and low systemic levels for these sub-
jects with medically refractory focal onset epilepsy.
Duration of therapeutic benefit depends, not so much on CSF
kinetics, as it does on the effect on brain tissue. There has long been a
belief that VPA has long-lasting effects [34] despite little detectable
binding to brain tissue [35] The mechanism of this possible long-act-
ing effect is unknown, as is its relevance to our current results.
This was a small study in a group of subjects with exceptionally
refractory epilepsy, demonstrating clear efficacy of the drug adminis-
tered in this manner, with relatively few drug-related side effects.
While significant initial problems with the devices implanted
occurred that required explantation and replacement, the datasuggest that ICV valproate may be tolerated in the long term and may
be effective in patients previously treated unsuccessfully with val-
proate orally. Potentially, alternative ASDs may be administered by
this method including those without suitable oral preparations. This
method is a first demonstration of CSF-infused antiepileptic medica-
tion in people with epilepsy and it introduces new treatment
options. Before adoption of this therapy, larger studies with appropri-
ate controls will be necessary.Author contributions
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